Reproducible, accurate, and absolute cell counting solutions for precise tracking of peripheral immune cell subpopulations at all clinical endpoints.
Cell enumeration has several key clinical applications, including disease progression monitoring, pharmacokinetics, and pharmacodynamics assessment.
At CellCarta, we produce reproducible cell counting solutions using state-of-the-art multiparametric flow cytometry that can simultaneously monitor cell composition and phenotypic dynamic changes.
We have expertise in optimizing assay methodologies according to your study’s specifications, including lyse/no-wash protocols and count normalization.
Our TBNK panels, cross-validated at all our global sites, allow for precise enumeration of T-cells, B-cells, and NK cells. Our off-the-shelf (OTS) offerings include:
Read our brochure to learn more.
Our workflow easily enumerates CD34+ progenitor cells in whole blood following mobilization using hematopoietic growth factors.
Our protocols follow guidelines established by ISHAGE (International Society of Hematotherapy and Graft Engineering), providing consistent, regulatory-ready results for transplant and cell therapy programs.
We can enumerate residual leukocytes for quality control of leukoreduced blood products. Our cell counting solutions provide a reliable, validated approach to confirming therapeutic efficacy, supporting product release and regulatory documentation.
We can support immunotherapy programs with cell counting solutions designed for the demands of complex clinical endpoints.
CellCarta enumerates CAR T-cells and myeloid-derived suppressor cells (MDSC) as part of a broader immune monitoring strategy, providing the absolute counts needed to track therapeutic activity and inform patient management decisions.
Our TBNK panels, cross-validated at all our global sites, allow for precise enumeration of T-cells, B-cells, and NK cells. Our off-the-shelf (OTS) offerings include:
Read our brochure to learn more.
Our workflow easily enumerates CD34+ progenitor cells in whole blood following mobilization using hematopoietic growth factors.
Our protocols follow guidelines established by ISHAGE (International Society of Hematotherapy and Graft Engineering), providing consistent, regulatory-ready results for transplant and cell therapy programs.
We can enumerate residual leukocytes for quality control of leukoreduced blood products. Our cell counting solutions provide a reliable, validated approach to confirming therapeutic efficacy, supporting product release and regulatory documentation.
We can support immunotherapy programs with cell counting solutions designed for the demands of complex clinical endpoints.
CellCarta enumerates CAR T-cells and myeloid-derived suppressor cells (MDSC) as part of a broader immune monitoring strategy, providing the absolute counts needed to track therapeutic activity and inform patient management decisions.
CellCarta scientists in flow cytometry and immunology. We have several platforms available to meet your study’s specifications, including Cytek™ Aurora spectral flow cytometers . Advanced data analysis is also possible through our CellEngine software.
Dependable cell counting solutions for deep clinical insights.
Easy Clinical Implementation
Platform Agnostic Workflow
Global Support
Flow Cytometry Experts
Customizable Solutions
Our vast service offerings in immunology can help progress your research further.
Assess immune cell division and cycling to evaluate treatment response and immune activation.
Measure basophil degranulation to assess allergic and hypersensitivity immune responses.
Advanced flow cytometry analysis and data visualization with incredible speed.
CellCarta's cell counting solutions cover a broad range of immune cell populations, including CD4/CD8 T-cells, CD19 B-cells, CD16/CD56 NK cells, CD34+ progenitor cells, monocytic and granulocytic MDSC, CAR T-cells, and residual leukocytes in leukoreduced blood products. Panel selection is guided by your study's therapeutic target and endpoint requirements.
Yes. Our standard TBNK panel carries IVD status, making it suitable for use in regulatory submissions when used according to specifications. Additionally, our standard TBNK and TBNK + CD20 panels are validated for secondary endpoint studies, and can be an invaluable tool for patient stratification, and multi-center trial requirements.
Yes. All cell counting solutions are cross-validated across CellCarta's global laboratory network. Panels are validated with the same level of rigor at each site, ensuring inter-site reproducibility and consistent data quality for multi-center studies.
Our team will work with you to discuss timelines and ensure all results are delivered on time, preventing unnecessary delays in trial progress. For example, our standardized TBNK workflows support official reporting within five days, providing the turnaround speed required for time-sensitive clinical decisions.
